Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial | Zendy

Serena Di Cosimo | Zendy; Jose Manuel PerezGarcía | Zendy; Meritxell Bellet | Zendy; Florence Dalenc | Zendy; Miguel GilGil | Zendy; Manuel Ruíz Borrego | Zendy; Joaquín Gavilá | Zendy; Miguel Sampayo-Cordero | Zendy; Elena Aguirre | Zendy; Peter Schmid | Zendy; Frederik Marmé | Zendy; Joseph Gligorov | Zendy; Andreas Schneeweiß | Zendy; Joan Albanell | Zendy; Pilar Zamora | Zendy; Duncan Wheatley | Zendy; Eduardo Martínez-De Dueñas | Zendy; Vicente Carañana | Zendy; Kepa Amillano | Zendy; Leonardo Mina | Zendy; Andrea Malfettone | Zendy; Javier Cortés | Zendy; Antonio LlombartCussac | Zendy

Open Access

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Author(s) -

Serena Di Cosimo,

Jose Manuel PerezGarcía,

Meritxell Bellet,

Florence Dalenc,

Miguel GilGil,

Manuel Ruíz Borrego,

Joaquín Gavilá,

Miguel Sampayo-Cordero,

Elena Aguirre,

Peter Schmid,

Frederik Marmé,

Joseph Gligorov,

Andreas Schneeweiß,

Joan Albanell,

Pilar Zamora,

Duncan Wheatley,

Eduardo Martínez-De Dueñas,

Vicente Carañana,

Kepa Amillano,

Leonardo Mina,

Andrea Malfettone,

Javier Cortés,

Antonio LlombartCussac

Publication year - 2022

Publication title -

the oncologist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.176

H-Index - 164

eISSN - 1549-490X

pISSN - 1083-7159

DOI - 10.1093/oncolo/oyac205

Subject(s) - medicine , fulvestrant , letrozole , neutropenia , palbociclib , tolerability , oncology , breast cancer , adverse effect , leukopenia , surgery , gastroenterology , cancer , metastatic breast cancer , chemotherapy , estrogen receptor , tamoxifen

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research